Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Leqembi

Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough.

Biogen stock dipped Wednesday despite an unexpected boost from its new Alzheimer's drug, Leqembi, and an earnings guidance hike.

Investors Business Daily

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning

Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.

Investors Business Daily

New dementia drug raises hopes and fears

These dementia treatments are opening uncharted territory. Here's some of what people should know

Salon

From analysis to the latest developments in health,
read the most diverse news in one place.

Insurers won't cover new Alzheimer's treatment for some customers

Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients

The Independent UK

Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates

Biogen stock dropped Tuesday after the biotechnology firm said it's eliminating 1,000 jobs as part of a strategy to cut operating expenses.

Investors Business Daily

Lilly applies for Alzheimer’s drug’s US approval after trial success

Eli Lilly & Co. said it applied for full U.S. approval of its Alzheimer’s disease drug that’s expected to compete with Eisai Co.’s Leqembi as the U.S. drugmaker revealed details of a final-stage trial at a conference in Amsterdam.

Tribune News Service

Sanders: Alzheimer's drug too expensive

"The high price of Leqembi threaten Medicare's finances, it will also negatively impact seniors on fixed incomes"

Salon

Read news from The Economist, FT, and more,
with one subscription

FDA approves new Alzheimer's drug

Leqembi has proven to slow the progression of the disease, while others only target its symptoms

Salon

FDA approves Leqembi, first drug to slow Alzheimer’s progression

Eisai and Biogen's Leqembi is the first drug to slow Alzheimer's progression to receive full FDA approval.

Axios

Alzheimer's drug Leqembi gets full FDA approval. Medicare coverage will likely follow

The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.

WEKU

FDA grants full approval to new Alzheimer’s drug - Roll Call

The drug Leqembi targets plaque buildup in the brain, and it is approved for people in the early stages of the disease.

Roll Call

Biogen Skids As Analysts Debate Uptake For Newly Approved Alzheimer's Drug

Biogen stock skidded Friday after the Food and Drug Administration fully approved its Alzheimer's treatment, Leqembi.

Investors Business Daily

Expected Alzheimer’s drug approval signals new era in treatment - Roll Call

The Alzheimer's drug's approval would trigger broader access under Medicare, but critics say it shouldn't be on the market at all.

Roll Call

Does Medicare pay for Alzheimer's drugs? The answer is complicated and changing

There are no drugs or treatments to cure Alzheimer’s disease, but emerging drugs may slow disease progression.

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - US

FDA advisers say new Alzheimer’s drug lecanemab slows cognitive decline

Panel’s opinion could pave way for full regulatory approval next month for treatment of disease that affects 6.5m Americans

Axios

Experimental Alzheimer's drug endorsed for full approval by FDA advisers

Leqembi could become the first treatment of its kind to receive traditional approval from the FDA.

Investors Business Daily

Biogen Rises After 'Drama-Free' Panel Votes Unanimously In Support Of Alzheimer's Drug

Biogen stock rose Monday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment.

Investors Business Daily

Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near

Biogen stock rose Wednesday after the FDA posted documents that suggest the agency will approve Alzheimer's treatment Leqembi.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.

Lilly's Alzheimer's treatment could reach blockbuster status by 2025, an analyst said Monday. Eli Lilly stock is trading near a record high.

The Independent UK

Why a new Alzheimer's drug is having a slow US debut

The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away

Tribune News Service

Commentary: Too soon to celebrate new Alzheimer’s drug

A treatment that improves Alzheimer’s disease would be a great advance, but Leqembi (lecanemab), which recently received accelerated approval from the FDA, is not that drug. Yes, lecanemab slows decline to an extent detectable on a test, but not to an extent that a relative or caretaker would notice. This…

The Independent UK

EXPLAINER: New drug slows Alzheimer's but comes with caveats

A new Alzheimer’s drug is hitting the market with experts voicing a lot of caution

Asharq Al-Awsat

US Approves New Drug to Treat Alzheimer's Disease

The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease. The FDA approval of the drug, Leqembi, also known as lecanemab, comes just days after the regulatory agency was harshly criticized…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Investor Business Daily

191 stories

the Food and Drug Administration

the Alzheimer Association

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.